Cargando…
Frontal Trigger Site Deactivation for Migraine Surgical Therapy
BACKGROUND: The World Health Organization ranked migraine as the 19th worldwide disease causing disability. Recent insights into the pathogenesis of migraine headache substantiate a neuronal hyperexcitability and inflammation involving compressed peripheral craniofacial nerves, and these trigger poi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209873/ https://www.ncbi.nlm.nih.gov/pubmed/32440458 http://dx.doi.org/10.1097/GOX.0000000000002813 |
_version_ | 1783531175822753792 |
---|---|
author | Raposio, Edoardo Simonacci, Francesco |
author_facet | Raposio, Edoardo Simonacci, Francesco |
author_sort | Raposio, Edoardo |
collection | PubMed |
description | BACKGROUND: The World Health Organization ranked migraine as the 19th worldwide disease causing disability. Recent insights into the pathogenesis of migraine headache substantiate a neuronal hyperexcitability and inflammation involving compressed peripheral craniofacial nerves, and these trigger points can be eliminated by surgery. In this study, we report our experience with minimally invasive surgical procedures for frontal migraine headache treatment. METHODS: From June 2011 to May 2019, we performed 70 frontal migraine decompression surgeries of both supratrochlear and supraorbital nerves (65 bilateral and 5 unilateral) by an endoscopic or transpalpebral approach. In 24 patients (34.2%), frontal migraine emerges as a secondary trigger point following primary occipital and/or temporal migraine surgery. RESULTS: After a mean follow-up of 24 months (range, 3–97 months), patients with frontal trigger site migraine reported a 94% positive response to surgery (32% complete relief and 62% significant improvement); 6% had no change in their symptoms. CONCLUSIONS: Based on our experience, the operation has not caused any serious complication or side effects, and surgical decompression of supraorbital and supratrochlear nerves might be recommended to patients who suffer from a moderate to severe chronic frontal migraine not responding to conventional therapy. |
format | Online Article Text |
id | pubmed-7209873 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-72098732020-05-21 Frontal Trigger Site Deactivation for Migraine Surgical Therapy Raposio, Edoardo Simonacci, Francesco Plast Reconstr Surg Glob Open Original Article BACKGROUND: The World Health Organization ranked migraine as the 19th worldwide disease causing disability. Recent insights into the pathogenesis of migraine headache substantiate a neuronal hyperexcitability and inflammation involving compressed peripheral craniofacial nerves, and these trigger points can be eliminated by surgery. In this study, we report our experience with minimally invasive surgical procedures for frontal migraine headache treatment. METHODS: From June 2011 to May 2019, we performed 70 frontal migraine decompression surgeries of both supratrochlear and supraorbital nerves (65 bilateral and 5 unilateral) by an endoscopic or transpalpebral approach. In 24 patients (34.2%), frontal migraine emerges as a secondary trigger point following primary occipital and/or temporal migraine surgery. RESULTS: After a mean follow-up of 24 months (range, 3–97 months), patients with frontal trigger site migraine reported a 94% positive response to surgery (32% complete relief and 62% significant improvement); 6% had no change in their symptoms. CONCLUSIONS: Based on our experience, the operation has not caused any serious complication or side effects, and surgical decompression of supraorbital and supratrochlear nerves might be recommended to patients who suffer from a moderate to severe chronic frontal migraine not responding to conventional therapy. Wolters Kluwer Health 2020-04-29 /pmc/articles/PMC7209873/ /pubmed/32440458 http://dx.doi.org/10.1097/GOX.0000000000002813 Text en Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Article Raposio, Edoardo Simonacci, Francesco Frontal Trigger Site Deactivation for Migraine Surgical Therapy |
title | Frontal Trigger Site Deactivation for Migraine Surgical Therapy |
title_full | Frontal Trigger Site Deactivation for Migraine Surgical Therapy |
title_fullStr | Frontal Trigger Site Deactivation for Migraine Surgical Therapy |
title_full_unstemmed | Frontal Trigger Site Deactivation for Migraine Surgical Therapy |
title_short | Frontal Trigger Site Deactivation for Migraine Surgical Therapy |
title_sort | frontal trigger site deactivation for migraine surgical therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209873/ https://www.ncbi.nlm.nih.gov/pubmed/32440458 http://dx.doi.org/10.1097/GOX.0000000000002813 |
work_keys_str_mv | AT raposioedoardo frontaltriggersitedeactivationformigrainesurgicaltherapy AT simonaccifrancesco frontaltriggersitedeactivationformigrainesurgicaltherapy |